At Rendez-vous Carnot 2025, the Institut Carnot OPALE is present with a clear objective:
to strengthen the dialogue between research, clinical practice, and industry around a shared challenge—better understanding and better treating leukemias and related diseases.
Throughout the event, the OPALE stand has become a space for discussion, exchange, and collective reflection on how translational research can more effectively serve patients.
Representing Institut Carnot OPALE on site are François Delhommeau, Anne Cromer, and Guillaume Menet, whose complementary expertise reflects the institute’s broader mission: bridging disciplines to accelerate therapeutic innovation.
Their presence underscores a central conviction shared by OPALE:
progress in leukemia does not emerge from isolated advances, but from continuous interaction between scientific discovery, clinical insight, and industrial development.
The conversations taking place at the OPALE stand go beyond networking. They address concrete questions:
How can academic research better anticipate clinical needs?
How can industry integrate early biological insight more effectively?
How can collaborative frameworks shorten the path from discovery to application?
These exchanges illustrate the role of events like Rendez-vous Carnot as connective tissue within the innovation ecosystem.
? Visit the OPALE stand at Rendez-vous Carnot 2025 to discuss current projects, collaborative opportunities, and shared ambitions in leukemia research.
Institut Carnot OPALE continues to position itself as a partner of choice for those seeking to build rigorous, integrated, and patient-relevant solutions in complex hematological diseases.